BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 26516927)

  • 21. Long noncoding RNA MALAT1 promotes malignant development of esophageal squamous cell carcinoma by targeting β-catenin via Ezh2.
    Wang W; Zhu Y; Li S; Chen X; Jiang G; Shen Z; Qiao Y; Wang L; Zheng P; Zhang Y
    Oncotarget; 2016 May; 7(18):25668-82. PubMed ID: 27015363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2.
    Li P; Zhang X; Wang H; Wang L; Liu T; Du L; Yang Y; Wang C
    Mol Cancer Ther; 2017 Apr; 16(4):739-751. PubMed ID: 28069878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2.
    Luo C; Merz PR; Chen Y; Dickes E; Pscherer A; Schadendorf D; Eichmüller SB
    Cancer Lett; 2013 Dec; 341(2):240-7. PubMed ID: 23962556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ulinastatin protects against lipopolysaccharide-induced cardiac microvascular endothelial cell dysfunction via downregulation of lncRNA MALAT1 and EZH2 in sepsis.
    Yu Z; Rayile A; Zhang X; Li Y; Zhao Q
    Int J Mol Med; 2017 May; 39(5):1269-1276. PubMed ID: 28405676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression.
    Luo M; Li Z; Wang W; Zeng Y; Liu Z; Qiu J
    Cancer Lett; 2013 Jun; 333(2):213-21. PubMed ID: 23354591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
    Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
    Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LncRNA MEG3 inhibits the progression of prostate cancer by facilitating H3K27 trimethylation of EN2 through binding to EZH2.
    Zhou Y; Yang H; Xia W; Cui L; Xu R; Lu H; Xue D; Tian Z; Ding T; Cao Y; Shi Q; He X
    J Biochem; 2020 Mar; 167(3):295-301. PubMed ID: 31790140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer.
    Ylipää A; Kivinummi K; Kohvakka A; Annala M; Latonen L; Scaravilli M; Kartasalo K; Leppänen SP; Karakurt S; Seppälä J; Yli-Harja O; Tammela TL; Zhang W; Visakorpi T; Nykter M
    Cancer Res; 2015 Oct; 75(19):4026-31. PubMed ID: 26282172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LncRNA SNHG17 promotes gastric cancer progression by epigenetically silencing of p15 and p57.
    Zhang G; Xu Y; Wang S; Gong Z; Zou C; Zhang H; Ma G; Zhang W; Jiang P
    J Cell Physiol; 2019 Apr; 234(4):5163-5174. PubMed ID: 30256413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer.
    Zhang A; Zhao JC; Kim J; Fong KW; Yang YA; Chakravarti D; Mo YY; Yu J
    Cell Rep; 2015 Oct; 13(1):209-221. PubMed ID: 26411689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EZH2 in Bladder Cancer, a Promising Therapeutic Target.
    Martínez-Fernández M; Rubio C; Segovia C; López-Calderón FF; Dueñas M; Paramio JM
    Int J Mol Sci; 2015 Nov; 16(11):27107-32. PubMed ID: 26580594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
    Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
    Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer.
    Lin YW; Ren LL; Xiong H; Du W; Yu YN; Sun TT; Weng YR; Wang ZH; Wang JL; Wang YC; Cui Y; Sun DF; Han ZG; Shen N; Zou W; Xu J; Chen HY; Cao W; Hong J; Fang JY
    J Pathol; 2013 Jul; 230(3):277-90. PubMed ID: 23424038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep.
    Li Y; Ren Y; Wang Y; Tan Y; Wang Q; Cai J; Zhou J; Yang C; Zhao K; Yi K; Jin W; Wang L; Liu M; Yang J; Li M; Kang C
    Theranostics; 2019; 9(16):4608-4623. PubMed ID: 31367244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16.
    Kong R; Zhang EB; Yin DD; You LH; Xu TP; Chen WM; Xia R; Wan L; Sun M; Wang ZX; De W; Zhang ZH
    Mol Cancer; 2015 Apr; 14():82. PubMed ID: 25890171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conditionally replicative adenovirus carrying shRNA targeting EZH2 inhibits prostate cancer growth and invasion.
    Xu SG; Yu JJ; Shi Q; Niu Q; Guo Z; Guo BY; Zhou GC; Gu X; Wu YX
    Oncol Rep; 2019 Jul; 42(1):273-282. PubMed ID: 31115564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2.
    Mukhopadhyay NK; Kim J; You S; Morello M; Hager MH; Huang WC; Ramachandran A; Yang J; Cinar B; Rubin MA; Adam RM; Oesterreich S; Di Vizio D; Freeman MR
    Oncogene; 2014 Jun; 33(25):3235-45. PubMed ID: 23893242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
    Tao T; Chen M; Jiang R; Guan H; Huang Y; Su H; Hu Q; Han X; Xiao J
    Oncol Rep; 2017 Mar; 37(3):1430-1436. PubMed ID: 28184935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer.
    Takayama K; Suzuki T; Tsutsumi S; Fujimura T; Urano T; Takahashi S; Homma Y; Aburatani H; Inoue S
    Oncotarget; 2015 Feb; 6(4):2263-76. PubMed ID: 25537508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LncRNA MALAT1 promotes epithelial-to-mesenchymal transition of esophageal cancer through Ezh2-Notch1 signaling pathway.
    Chen M; Xia Z; Chen C; Hu W; Yuan Y
    Anticancer Drugs; 2018 Sep; 29(8):767-773. PubMed ID: 29916899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.